VRAX - Latest News
Virax Biolabs Group Limited (VRAX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $643,856. Beta to the broader market is 1.33.
The article list below shows the most recent VRAX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent VRAX Headlines
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
prnewswire.com - Jul 16, 2026
Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6. 4 million, total assets of $8.
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
prnewswire.com - Jul 10, 2026
LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) today closed its previously announced exer
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
prnewswire.com - Jul 9, 2026
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a
Why this biotech stock more than tripled on Thursday
invezz.com - Jul 9, 2026
Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough. In a pre
Why Did Virax Biolabs Stock Triple In One Session?
benzinga.com - Jul 9, 2026
Virax Biolabs Group Limited (NASDAQ:VRAX) stock is up during Thursday's premarket session, as the company has signed a multi-country commercial supply
How News Affects VRAX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track VRAX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked VRAX news questions
- What is the latest VRAX news headline?
- The most recent VRAX headline (Jul 16, 2026) is "Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the VRAX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What VRAX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual VRAX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.